← Leaderboards
Marshall R Posner
Beth Israel Deaconess Medical Center
$5,601,889
Attributed
$5,601,889
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $784K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,601,889 · 8
By mechanism
R01$3,185,685 · 2
R21$1,225,835 · 2
P30$1,127,301 · 3
R56$63,068 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Gerburg M Wulf$4,301,499
- Ashok K Saluja$17,794,278
- Michael Scott Seaman$1,441,802
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsMemberCancer CareBaseInnovationCancer TherapyMissionCancer Clinical TrialLaboratoriesTranslatingCancer Center Support GrantFutureClinical ResearchImmune SystemClinical TrialsBackInstitutesResearch PersonnelResponseNeutralizing AntibodyReportingSafetyComplement
Grant awards (25)
Cancer Clinical Investigation$250,000
P30 · FY2024 · CA · contact PI
Cancer Clinical Investigation$26,344
P30 · FY2024 · CA · contact PI
Cancer Clinical Investigation$26,344
P30 · FY2023 · CA · contact PI
Cancer Clinical Investigation$26,344
P30 · FY2022 · CA · contact PI
Developing a Therapeutics Platform for Adenoid Cystic Carcinoma$211,875
R21 · FY2021 · DE · contact PI
Cancer Clinical Investigation$26,344
P30 · FY2021 · CA · contact PI
Developing a Therapeutics Platform for Adenoid Cystic Carcinoma$254,250
R21 · FY2020 · DE · contact PI
Cancer Clinical Investigation$26,344
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core-007)$149,265
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core-007)$164,991
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core-007)$164,991
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core-007)$164,990
P30 · FY2016 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core-007)$101,344
P30 · FY2015 · CA · contact PI
EBV-Specific T-Cell Therapy for Nasopharynx Cancer: Immunomodulation and Response$370,980
R21 · FY2009 · CA · contact PI
Functional Mechanisms of Antibody Inhibition of HIV-1$395,320
R01 · FY2008 · AI · contact PI
EBV-Specific T-Cell Therapy for Nasopharynx Cancer: Immunomodulation and Response$388,730
R21 · FY2008 · CA · contact PI
Functional Mechanisms of Antibody Inhibition of HIV-1$402,977
R01 · FY2007 · AI · contact PI
Functional Mechanisms of Antibody Inhibition of HIV-1$170,000
R01 · FY2007 · AI · contact PI
Functional Mechanisms of Antibody Inhibition of HIV-1$411,595
R01 · FY2006 · AI · contact PI
Functional Mechanisms of Antibody Inhibition of HIV-1$357,383
R01 · FY2005 · AI
Functional Mechanisms of Antibody Inhibition of HIV-1$63,068
R56 · FY2005 · AI
HUMAN MONOCLONAL ANTIBODIES TO STUDY AND TREAT HIV$369,153
R01 · FY2003 · AI
HUMAN MONOCLONAL ANTIBODIES TO STUDY AND TREAT HIV$358,401
R01 · FY2002 · AI
HUMAN MONOCLONAL ANTIBODIES TO STUDY AND TREAT HIV$354,461
R01 · FY2001 · AI
HUMAN MONOCLONAL ANTIBODIES TO STUDY AND TREAT HIV$366,395
R01 · FY2000 · AI